Renal denervation is recommended by the 2019 Taiwan consensus statement for 5 specific subgroups of uncontrolled hypertensive patients following rigorous anatomical and clinical assessments.
The 2019 Taiwan consensus statement provides structured recommendations for patient selection and clinical assessment for renal denervation in hypertension management.
. Five subgroups of hypertensive patients are deemed preferred candidates for RDN and dubbed "RDN i2": Resistant hypertension, patients with hypertension-mediated organ Damage, Non-adherent to antihypertensive medications, intolerant to antihypertensive medications, and patients with secondary (2ndary) causes being treated for ≥ 3 months but BP still uncontrolled. The Task Force recommends assessment of three aspects, dubbed "RAS" (R for renal, A for ambulatory, S for secondary), beforehand to ascertain whether RDN could be performed appropriately: 1) Renal artery anatomy eligibility assessed by computed tomography or magnetic resonance renal angiography if not contraindicated, 2) genuine uncontrolled BP confirmed by 24-hour Ambulatory BP monitoring, and 3) Secondary hypertension identified and properly treated. After the procedure, 24-hour ambulatory BP monitoring, together with the dose and dosing interval of all BP-lowering drugs, should be obtained 6 months following RDN. Computed tomography or magnetic resonance renal angiography should be obtained 12 months following RDN, given that renal artery stenosis might not be clinically evident.
Wang et al. (Wed,) conducted a review in Arterial Hypertension. Renal Denervation was evaluated. Renal denervation is recommended by the 2019 Taiwan consensus statement for 5 specific subgroups of uncontrolled hypertensive patients following rigorous anatomical and clinical assessments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: